HBK Sorce Advisory’s Lexicon Pharmaceuticals LXRX Stock Holding History

HBK Sorce Advisory’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.9K	Hold	11,786	–	–	﹤0.01%	659
2026 Q1	$23.6K	Hold	11,786	–	–	﹤0.01%	651
2025 Q4	$14.5K	Hold	11,786	–	–	﹤0.01%	623
2025 Q3	$18K	Hold	11,786	–	–	﹤0.01%	617
2025 Q2	$11.1K	Buy	+11,786	New	+$7.64K	﹤0.01%	594

Other funds holding LXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

HBK Sorce Advisory's LXRX Position: Q2 2026 in Review

HBK Sorce Advisory held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 11,786 shares worth $28.9K. The position accounts for ﹤0.01% of the portfolio, ranked #659.

HBK Sorce Advisory first reported a position in LXRX in Q2 2025 and has held it in 5 quarters since. 51 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

HBK Sorce Advisory held 11,786 shares of Lexicon Pharmaceuticals worth $28.9K as of Q2 2026.
HBK Sorce Advisory left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
Lexicon Pharmaceuticals made up ﹤0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #659 holding.
HBK Sorce Advisory first reported a position in Lexicon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
51 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.